MOTS-c cost: prescription vs research grade
Published prices by category, checked November 2, 2026. REMEVi does not currently price MOTS-c.
Published prices for compounded MOTS-c are scarce. One telehealth listing, dated before HHS’s October 2026 policy, shows a monthly program price in the low hundreds of dollars; we found no published clinic price. MOTS-c is not FDA-approved. REMEVi does not currently price MOTS-c or offer it, and has no MOTS-c product.
MOTS-c is not FDA-approved. Since HHS’s October 2026 interim policy, a state-licensed 503A pharmacy may compound it on a patient-specific prescription under listed conditions.
REMEVi does not currently offer MOTS-c.
Published MOTS-c prices by category
| Category | Published figure | What the figure covers | Published by |
|---|---|---|---|
| Telehealth peptide programs | $280 per month | One listed program, subcutaneous; listing says video consultation and lab testing included; status dated February 2026, before the policy | Telehealth comparison site |
| Clinic programs | No published price found (checked 2026-11-02) | — | — |
| Research-grade vials | No published price cited (checked 2026-11-02) | The listings found were seller pages, which this page does not link | — |
Figures are as published by third parties and are not REMEVi prices. The listing predates the October 30, 2026 policy, so programs may change it.
What the CoA and registered-source rules add
Under the HHS policy, the pharmacy must buy bulk MOTS-c from an FDA-registered facility with a valid certificate of analysis, from a CGMP-compliant manufacturer, compound one active ingredient per product, and package it with no device other than a 510(k)-cleared syringe. Each step costs money, and so does the prescriber’s evaluation and follow-up.
Why “research grade” MOTS-c is cheaper, and what it lacks
Research-grade vials skip the prescription, the 503A pharmacy and the sourcing documentation, so they cost less. They are outside the HHS policy, are not made for a named patient, and carry no requirement for a CoA or a registered source. FDA warned five online peptide vendors on August 24, 2026 that “research use only” labels did not outweigh evidence of human use.
REMEVi and MOTS-c
REMEVi does not currently price MOTS-c and does not offer it. What REMEVi does offer, with the same prescription-and-licensed-pharmacy model, is NAD+: From $149 per 4 weeks on the 52-week plan ($1,937 for 13 fills).
More questions
How much does MOTS-c cost?
Published prices for compounded MOTS-c are scarce. One telehealth listing, dated before HHS’s October 2026 policy, shows a monthly program price in the low hundreds of dollars; we found no published clinic price. MOTS-c is not FDA-approved. REMEVi does not currently price MOTS-c or offer it, and has no MOTS-c product.
Sources
- Telehealth Ally — MOTS-c: Evidence, FDA Status & Telehealth Providers (status updated Feb 1, 2026) (read November 2, 2026)
- HHS, Federal Register — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526, October 30, 2026) (read November 2, 2026)
- Holtz, Beaver & Rosen (Foley & Lardner), National Law Review, Oct 30, 2026 — HHS Announces Limited Enforcement Discretion for Compounding of Six Peptides (read November 2, 2026)
- Holland & Knight, Oct 16, 2026 — Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions (read November 2, 2026)
Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·